DNA Jan 2025 0.500 call
| Previous Close | 0.6100 |
| Open | 0.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.5500 - 0.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
PR NewswireGinkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
Simply Wall St.Recent uptick might appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners after losing 25% over the past year
Key Insights Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive to...
PR NewswireGinkgo Bioworks Announces Date of First Quarter 2024 Results Presentation
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET.
